# Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer

> **NCT01804790** · PHASE3 · COMPLETED · sponsor: **UNICANCER** · enrollment: 461 (actual)

## Conditions studied

- Cancer of the Rectum

## Interventions

- **DRUG:** mFolfirinox
- **RADIATION:** Radiotherapy 50 Gy
- **DRUG:** Capecitabine
- **PROCEDURE:** TME surgery
- **DRUG:** mFolfox6 or capecitabine

## Key facts

- **NCT ID:** NCT01804790
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 461 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01804790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01804790, "Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT01804790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*